Key Takeaways
- • Healthcare IT has delivered superior returns versus other healthcare subsectors since 2017, with deal volumes growing to nearly 20% of healthcare transactions in 2025 compared to 15% in 2021, reflecting sustained private equity appetite across macroeconomic cycles.
- • Leading PE investors are achieving Rule of 60 outcomes through three core value creation levers: pricing and packaging optimization, cross-selling expansion, and AI-enabled growth and margin expansion—moving beyond end-user adoption as the sole return driver.
- • Consistent, disciplined value creation execution from underwriting through exit distinguishes highest-returning deals, with winning investors emphasizing scale, revenue visibility, and selective platform and tuck-in acquisition strategies.
- • Generative AI represents both significant top- and bottom-line value creation opportunity and navigable downside risk for healthcare IT providers, requiring strategic assessment during underwriting and throughout the investment lifecycle.
- • Major 2025 flagship transactions underscore sector strength: Warburg Pincus sold majority stake in ModMed (specialty EMR) to Clearlake Capital and Bain Capital; Bain Capital acquired HealthEdge from Blackstone and merged it with HealthProof (payer IT); Bain Capital also invested in Softway Medical Group in France.
Summary
The differentiation between winning and underperforming healthcare IT investments has sharpened considerably. Beyond traditional end-user adoption metrics, leading PE investors are now systematically capturing value through three specific mechanisms: pricing and packaging optimization (extracting margin through product tiering and bundled offerings), cross-selling expansion (leveraging portfolio companies to penetrate adjacent customer segments), and AI-enabled growth and margin expansion (deploying generative AI to enhance both revenue and operational efficiency). Investors achieving Rule of 60 outcomes—a metric combining revenue growth and EBITDA margin—demonstrate disciplined execution across these levers from deal underwriting through exit planning.
Strategic deal selection itself proves critical to returns. Winning investors emphasize platform acquisition targeting scale, revenue visibility, and defensible market positions, followed by selective tuck-in acquisitions that enhance capabilities or customer access rather than standalone bolt-on plays. This disciplined approach to portfolio construction, combined with rigorous value creation planning, sets apart the highest-returning vehicles from the broader cohort.
The emergence of generative AI as both opportunity and risk reflects the sector's maturation. Healthcare IT providers can deploy AI to improve clinical outcomes, enhance provider workflows, and optimize payer operations—creating genuine top-line and bottom-line value. However, competitive AI adoption risks require careful underwriting and continuous strategic navigation throughout the investment period.
The 2025 transaction landscape validated these principles through flagship deals: Warburg Pincus exited its majority stake in ModMed, a specialty-focused EMR provider, to Clearlake Capital and Bain Capital. In parallel, Bain Capital executed a platform consolidation by acquiring HealthEdge (payer IT) from Blackstone and merging it with HealthProof, creating a scaled payer-focused platform. Internationally, Bain Capital's investment in Softway Medical Group, a France-based health information system and EMR provider, reflects geographic diversification within the sector.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.